Hyperprolactinemia in the postmenopause: versions and contraversions

The prevalence of hyperprolactinemia in postmenopausal women is unknown and has been estimated as infrequent by many studies. Prolactinomas found after menopause are usually macroadenomas and remain unrecognized for a long time due to atypical clinical signs or their absence. The growth potential of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Olga Ya. Leshchenko
Formato:	article
Lenguaje:	RU
Publicado:	"Consilium Medicum" Publishing house 2021
Materias:	hyperprolactinemia prolactinoma postmenopausal period climacteric Medicine R
Acceso en línea:	https://doaj.org/article/e4db7490e06e4fa48832f8a2b721a257
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e4db7490e06e4fa48832f8a2b721a257
record_format	dspace
spelling	oai:doaj.org-article:e4db7490e06e4fa48832f8a2b721a2572021-12-01T12:22:37ZHyperprolactinemia in the postmenopause: versions and contraversions0040-36602309-534210.26442/00403660.2021.10.201073https://doaj.org/article/e4db7490e06e4fa48832f8a2b721a2572021-10-01T00:00:00Zhttps://ter-arkhiv.ru/0040-3660/article/viewFile/87137/65319https://doaj.org/toc/0040-3660https://doaj.org/toc/2309-5342The prevalence of hyperprolactinemia in postmenopausal women is unknown and has been estimated as infrequent by many studies. Prolactinomas found after menopause are usually macroadenomas and remain unrecognized for a long time due to atypical clinical signs or their absence. The growth potential of prolactinomas persists after menopause, most of them are invasive and accompanied by high prolactin levels. Treatment with dopamine agonists is usually long-term, the goals of which are to reduce tumor size, normalize prolactin levels and the negative effects of hyperprolactinemia. Treatment with cabergoline makes it possible to achieve remission of the disease in the first years after discontinuation, however, the proportion of relapses in postmenopausal women increases 5 years after discontinuation of the drug. Remission of prolactinomas is not evident in postmenopausal women. The modern management of patients with prolactinoma and/or hyperprolactinemia does not have clear positions in the postmenopausal period. Controversial issues remain: an ambiguous relationship between prolactin levels and breast cancer, there are no convincing conclusions on the improvement of bone mineral density and/or a decrease in the risk of fractures with normalization of prolactin levels, there are no data on metabolic parameters after the end of treatment with dopamine agonists, conflicting information about the relationship of prolactin levels and the severity of the manifold manifestations of the climacteric syndrome. The use of estrogen-progestin drugs in women with hyperprolactinemia/prolactinomas is also not well understood. Thus, the problem of hyperprolactinemia in the perimenopausal and postmenopausal period is underestimated and requires additional research, as well as the development of diagnostic and therapeutic strategies for potential benefits in terms of weight loss, improving insulin sensitivity, reducing the risk of fractures, maintaining sexuality and psycho-emotional well-being.Olga Ya. Leshchenko"Consilium Medicum" Publishing housearticlehyperprolactinemiaprolactinomapostmenopausal periodclimactericMedicineRRUТерапевтический архив, Vol 93, Iss 10, Pp 1234-1239 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	hyperprolactinemia prolactinoma postmenopausal period climacteric Medicine R
spellingShingle	hyperprolactinemia prolactinoma postmenopausal period climacteric Medicine R Olga Ya. Leshchenko Hyperprolactinemia in the postmenopause: versions and contraversions
description	The prevalence of hyperprolactinemia in postmenopausal women is unknown and has been estimated as infrequent by many studies. Prolactinomas found after menopause are usually macroadenomas and remain unrecognized for a long time due to atypical clinical signs or their absence. The growth potential of prolactinomas persists after menopause, most of them are invasive and accompanied by high prolactin levels. Treatment with dopamine agonists is usually long-term, the goals of which are to reduce tumor size, normalize prolactin levels and the negative effects of hyperprolactinemia. Treatment with cabergoline makes it possible to achieve remission of the disease in the first years after discontinuation, however, the proportion of relapses in postmenopausal women increases 5 years after discontinuation of the drug. Remission of prolactinomas is not evident in postmenopausal women. The modern management of patients with prolactinoma and/or hyperprolactinemia does not have clear positions in the postmenopausal period. Controversial issues remain: an ambiguous relationship between prolactin levels and breast cancer, there are no convincing conclusions on the improvement of bone mineral density and/or a decrease in the risk of fractures with normalization of prolactin levels, there are no data on metabolic parameters after the end of treatment with dopamine agonists, conflicting information about the relationship of prolactin levels and the severity of the manifold manifestations of the climacteric syndrome. The use of estrogen-progestin drugs in women with hyperprolactinemia/prolactinomas is also not well understood. Thus, the problem of hyperprolactinemia in the perimenopausal and postmenopausal period is underestimated and requires additional research, as well as the development of diagnostic and therapeutic strategies for potential benefits in terms of weight loss, improving insulin sensitivity, reducing the risk of fractures, maintaining sexuality and psycho-emotional well-being.
format	article
author	Olga Ya. Leshchenko
author_facet	Olga Ya. Leshchenko
author_sort	Olga Ya. Leshchenko
title	Hyperprolactinemia in the postmenopause: versions and contraversions
title_short	Hyperprolactinemia in the postmenopause: versions and contraversions
title_full	Hyperprolactinemia in the postmenopause: versions and contraversions
title_fullStr	Hyperprolactinemia in the postmenopause: versions and contraversions
title_full_unstemmed	Hyperprolactinemia in the postmenopause: versions and contraversions
title_sort	hyperprolactinemia in the postmenopause: versions and contraversions
publisher	"Consilium Medicum" Publishing house
publishDate	2021
url	https://doaj.org/article/e4db7490e06e4fa48832f8a2b721a257
work_keys_str_mv	AT olgayaleshchenko hyperprolactinemiainthepostmenopauseversionsandcontraversions
_version_	1718405206919610368

Hyperprolactinemia in the postmenopause: versions and contraversions

Ejemplares similares